Target Large-Scale Biologics Aktiv Medical Systems specializes in a gas-driven Direct Drive autoinjector platform capable of delivering up to 5.5 mL at high viscosity (up to 600 cP), addressing a market need for large-dose biologics and offering a compelling value proposition to pharmaceutical partners seeking self-administration options for their sizable patient populations.

Partner With Pharma With a focus on enabling pharmaceutical partners to bring more patients home for self-administration, pursue collaborations with mid to large biotech and pharma companies developing high-dose biologics, especially where current autoinjectors fall short on volume or viscosity.

Public Sector Funding Historical government and BARDA-related funding and programs (AKTiVax/AktiVax lineage) indicate receptiveness to U.S. government-backed autoinjector initiatives; leverage grant-ready narratives and potential government-sponsored pilots to co-develop manufacturing lines for autoinjector platforms.

Expansion and Talent The company’s growth trajectory, including past office expansion and proximity to major talent hubs (Denver metro area), suggests opportunities to collaborate on regional manufacturing scale-up, talent pipelines, and co-investment in process development to accelerate supply readiness.

Complementary Technologies Existing tech footprint around Squarespace commerce, digital assets, and analytics indicates readiness for partner ecosystem integrations, digital trial enrollment, and streamlined procurement channels; propose joint go-to-market plans that integrate digital ordering, program management, and device tracking.